Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
software product development
Popular Articles
Teeth Whitening

Potential Key To Maintaining Embryonic Stem Cells In Lab
In a new study that could transform embryonic stem cell (ES cell) research, scientists at UT Southwestern Medical Center have discovered why mouse ES cells can be easily grown in a laboratory while other mammalian ES cells are difficult, if not impossible, to maintain.
generic viagra online
Manchester Clinical Psychologist Wins May Davidson Award, UK
Dr Sam Cartwright-Hatton from the University of Manchester has won this year"s May Davidson Award. The award is made each year by the British Psychological Society"s Division of Clinical Psychology to someone who has made an outstanding contribution to the development of clinical psychology within the first 10 years of their career.
plastic surgery before after
News of the day
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company"s major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer"s disease. As progress in those programs has been made, Eisai announces the status as follows:
Cardiovascular

Warning Issued Over Proposed Drug Company Promotion Of Medicines To Public, UK

Drug companies may exploit new rules to promote their products to the public but present it as mere provision of information, according to an editorial published this week in the Drug and Therapeutics Bulletin (DTB). Direct advertising of prescription-only medicines to the public is currently not allowed in the European Union (EU), but this position may be undermined by proposals from the European Commission (EC). The proposals, if agreed, would allow drug companies new opportunities to present the public with information about prescription-only medicine through the internet or yet-to-be-defined "health-related publications." The DTB editorial is concerned about the proposals, which it suggests would permit direct advertising to the public in spite of the EU-wide ban. It is proposed that each EU member state would ensure the companies providing the information were monitored and this could involve self-regulation by the companies. "A key concern about these ideas is the intrinsic difficulty in distinguishing between advertising of prescription-only medicines to the public (which would still be banned) and proactive provision of non-promotional information about such products," says the editorial. The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency, is currently carrying out a public consultation on this issue - due to finish on August 14 - but supports the principle of allowing the pharmaceutical industry to give patients more information about medicines. DTB, however, cites the negative experience in the US with direct to consumer advertising, where "infringements of rules on information provision have tended to be detected far too late and where there have been difficulties in imposing effective penalties." The editorial concludes: "We believe that acceptance of the EC"s proposals would permit public dissemination of promotional information about prescription-only medicines, masquerading as "information provision"." Given the obvious conflict of interests, DTB concludes, it would be naç¯ve to think that the pharmaceutical industry would provide independent and reliable information to allow people to make informed choices about treatment. "How to misinform patients." DTB 2009; doi 10.1136/dtb.2009.07.0027 Drug And Therapeutics Bulletin


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009